NAD-supplementation in Drug naïve Parkinson's Disease

Sponsor / Institution: Haukeland University Hospital

Purpose

Determine if NR has an impact on the neurometabolic profile of patients with PD as measured by [18F] fluorodeoxyglucose (FDG)-positron emission tomography (FDG-PT). As well as to determine whether high dose oral NR improves motor symptoms associated with PD, and to determine whether high dose oral NR rectifies NAD metabolism and increase NAD levels in body fluids and muscle tissue.

Study Design

Randomized, double blind, placebo- controlled, parallel assignment

Dose

2x 250mg 2x/day (500mg 2x/day total)

Length of Intervention

30 days

Intrinsic Capacity

Locomotion

Status

Completed

Condition or Disease 

Parkinson Disease
Neurodegenerative Diseases

Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.

Clinical Studies, Locomotion, CompletedANAD Staff